

# The Effects of Sodium Ions on Ligand Binding and Conformational States of G Protein-Coupled Receptors—Insights from Mass Spectrometry

Mark T. Agasid, Lars Sørensen, Leonhard H. Urner, Jun Yan, and Carol V. Robinson\*



**ABSTRACT:** The use of mass spectrometry to investigate proteins is now well established and provides invaluable information for both soluble and membrane protein assemblies. Maintaining transient noncovalent interactions under physiological conditions, however, remains challenging. Here, using nanoscale electrospray ionization emitters, we establish conditions that enable mass spectrometry of two G protein-coupled receptors (GPCR) from buffers containing high concentrations of sodium ions. For the Class A GPCR, the adenosine 2A receptor, we observe ligand-induced changes to sodium binding of the receptor at the level of individual sodium ions. We find that antagonists promote sodium binding while agonists attenuate sodium binding. These findings are in line with high-resolution X-ray crystallography wherein only inactive conformations retain sodium ions in allosteric binding pockets. For the glucagon receptor (a Class B GPCR) we observed enhanced ligand binding in electrospray buffers containing high concentrations of sodium, as opposed to ammonium acetate buffers. A combination of native and -omics mass spectrometry revealed the presence of a lipophilic negative allosteric modulator. These experiments highlight the advantages of implementing native mass spectrometry, from electrospray buffers containing high concentrations of physiologically relevant salts, to inform on allosteric ions or ligands with the potential to define their roles on GPCR function.

ore than 800 G protein-coupled receptors (GPCRs), Mencoded in the human proteome, regulate many physiological processes, making GPCRs intensively studied drug targets to combat human pathophysiology. Collectively, GPCRs account for 34% of all small-molecule drug targets.<sup>1</sup> Beyond a traditional orthosteric ligand binding site, GPCRs also harbor allosteric pockets that bind a host of endogenous ions, peptides, lipids, and intracellular proteins that coregulate GPCR function.<sup>2</sup> One of the most well-known, but enigmatic examples involves a conserved sodium binding pocket in Class A GPCRs. High-resolution X-ray crystallography structures of several GPCRs identified this highly conserved pocket that is occupied by a Na<sup>+</sup> ion in the inactive conformation.<sup>3</sup> In active state conformations, this sodium ion-binding pocket collapses, with possible egress of the ion into the cytoplasm.<sup>4</sup> This binding pocket is important with functional and mutagenesis studies revealing the inverse agonist effects of sodium ions on GPCRs. Its functional importance has been described as an ionic microswitch that couples the extracellular domain with the intracellular structural changes associated with heterotrimeric G protein coupling.<sup>5,6</sup> However, it has been difficult to affirm concurrent changes in receptor sodium occupancy by traditional biochemical or functional assays.<sup>3</sup> Moreover since other allosteric binding sites have been reported for divalent cations, and lipophilic positive and negative allosteric modulators,<sup>7–10</sup> controlling these allosteric sites to modulate GPCR function serves as a potential route for therapeutic intervention.<sup>11</sup>

Native mass spectrometry (nMS) has become a powerful biophysical tool to characterize membrane proteins, including

relatively few examples of GPCRs.<sup>12,13</sup> nMS exploits the gentle ionization conditions enabled by nanoelectrospray ionization (nESI),<sup>14</sup> which can preserve noncovalent interactions, informing on protein–ligand and protein–protein interactions.<sup>15</sup> The high resolution afforded by state-of-the-art instruments have recently identified a previously unknown GPCR-lipid interaction that enhances coupling to  $G\alpha_{s}$ ,<sup>16</sup> and defined the effect of post-translational modifications on ligand binding to GPCRs.<sup>17</sup> Very recently, hybridization of nMS with "omics" based platforms has enabled tandem MS (MS<sup>n</sup>) to perform nMS, proteoform and ligand identification.<sup>18</sup>

In general, nMS experiments rely on exchanging proteins from biochemical assay buffers (i.e., >100 mM salt) into MScompatible solutions composed of volatile agents, e.g., ammonium acetate (NH<sub>4</sub>OAc), to avoid detrimental effects of nonvolatile salts during the nESI process.<sup>19</sup> These adverse effects include generation of salt clusters and the formation of nonspecific adducts with protein ions, which distribute the signal over multiple adduct states, thereby suppressing ion intensity, decreasing mass accuracy, resolution, and detection limits. To overcome these experimental limitations, nanoscale nESI tips (60–600 nm) (nanoemitters) have shown initial

Received: November 11, 2020 Published: March 12, 2021





promise for their greater salt tolerance, owing to the smaller electrospray droplets generated.  $^{\rm 20-22}$ 

Here we describe the use of ~100 nm diameter nanoemitters to study two GPCRs—a thermostabilized variant of the prototypical Class A GPCR, the adenosine 2A receptor (A2aR),<sup>23</sup> and a Class B GPCR, the wild-type glucagon receptor (GCGR). We have exploited the benefits of the nanoemitters to show how ligand type affects sodium occupancy of A2aR and how physiologically relevant solution conditions preserve lipophilic drug binding to GCGR.

Since high-resolution structures of A2aR, captured in inactive and active conformations, were the first to underscore the importance of sodium ions in modulating function, we used this receptor for our initial investigation (Figure 1A). We



**Figure 1.** Ligand dependent effects on the sodium bound states of A2aR. (A) Schematic illustrating the sodium binding pocket of A2aR in an inactive conformation (PDB 4EIY) and the collapse of the pocket upon adopting an active conformation (PDB 3QAK). 13+ charge state of A2aR electrosprayed from (B) 200 mM NH<sub>4</sub>OAc and (C) 50 mM NaCl, 5 mM Tris (both pH 7.5 with 2× CMC LMNG) in the absence or presence of 10  $\mu$ M ligand. Spectra are representative of  $n \ge 4$  nanoemitters and 2 protein preparations.

first optimized the nanoemitter orifice size and compared results with spectra recorded for microemitter tips in NH<sub>4</sub>OAc on a Q-Exactive UHMR mass spectrometer (Figure S1). Nanoemitter diameters of 115  $\pm$  11 nm yielded reproducible spectra for most soluble and membrane proteins examined, including A2aR (Figure S2). Importantly nanoemitters produced similar mass A2aR (46526.7  $\pm$  0.5 Da vs 46527.1  $\pm$  0.5 Da) and average charge states ( $Z_{ave}$  12.33  $\pm$  0.13 vs 12.41  $\pm$  0.16). The extent of collisional activation required to remove LMNG detergent from the A2aR was also similar (Figure S3 and S4). Remarkably, A2aR electrosprayed from NaCl/Tris solutions produced an apo state protein ion (i.e., no sodium ions bound) as well as protein ions with up to seven readily resolved sodium binding events (Figure S5). Additionally, lipid adducts that copurified with A2aR were readily

discerned in mass spectra (Figure S4). These results illustrate the capability of nanoemitters to produce high-resolution spectra directly from high concentrations of sodium that better mimic biochemical assay conditions.<sup>19,21</sup>

We next investigated differences in sodium binding properties induced by agonists and antagonists (structures Figure S6). A2aR incubated with 10  $\mu$ M of the nonselective agonist NECA  $(K_{\rm d} \approx 100 \text{ nM})^{24}$  or the highly selective A2aR agonist CGS 21680  $(K_d \approx 65-117 \text{ nM})^{25}$  produced spectra from NH<sub>4</sub>OAc solutions devoid of any bound sodium ions, similar to A2aR without ligand (Figure 1B). Interestingly, incubation with the antagonists XAC  $(K_d \approx 10 \text{ nM})^{24}$  or ZM241385  $(K_d \approx 2$  $nM)^{24}$  retained at least one sodium on the receptor, even after buffer exchange into NH<sub>4</sub>OAc. Spectra obtained in NaCl/Tris with antagonists consistently showed a much greater retention of sodiums (from 1 to 7), whereas the presence of agonist significantly attenuated the intensities of sodium bound states, especially for CGS 21680 (Figure 1C and Figures S7-S10). The sodium adduct intensities were minimally affected by increased collisional activation (Figure S11). Intriguingly these results provide complementary evidence for changes in the sodium-bound states between active and inactive Class A GPCRs.

While nMS aims to retain noncovalent interactions some interactions have been challenging to preserve, particularly small-molecule ligands bound to membrane proteins in detergent micelles. Although some exceptions exist,1' in these experiments we did not detect binding of the agonists and antagonists (Figure S4C,D), yet we observed clear effects of their presence on sodium binding. Previous studies on membrane protein-lipid binding events highlighted the complex interplay of lipid headgroup chemistry, available charged residues at the protein surface, and electrospray polarity (i.e., positive or negative).<sup>26</sup> As the structures of A2aR ligand employed in this study (Figure S6) have a propensity to be positively charged, this may inhibit binding to postiviely charged protein ions explaining the absence of peaks corresponding to ligand binding.

To confirm that the differences observed in A2aR sodium occupancy resulted from ligand-induced conformational changes we performed a competition assay. We incubated the receptor in NH<sub>4</sub>OAc first with antagonist ZM241385 and then challenged the solution with 40-fold excess of the agonist NECA. Comparing the sodium binding peaks following incubation with ZM241385 alone and after challenge with NECA (Figures S12) reveals depletion of sodium binding. This reduction is consistent with solution phase experiments depicting collapse of allosteric binding pocket and egress of the sodium ion when A2aR adopts an active conformation in the presence of high concentrations of agonist, in anticipation of G protein coupling.<sup>5</sup> In NaCl/Tris solutions, the loss of more than one sodium ion between agonized and antagonized states is consistent with the  $NH_4OAc$  experiments (Figure 1C). Moreover, the similarity in sodium adduct pattern in the apo (ligand-free state) versus antagonized states for NaCl/Tris, reflects the inverse agonist pharmacology of sodium ions that stabilize an inactive conformation.<sup>27</sup> Furthermore, molecular dynamics (MD) simulations along the conformational landscape of A2aR indicate the potential for more than one sodium ion-binding site beyond the canonical site identified by X-ray crystallography.<sup>2</sup>

Turning to the glucagon receptor (GCGR), we optimized solution conditions and found that the recently developed

oligoglycerol detergent, G1,<sup>29</sup> and cholesteryl hemisuccinate (CHS) mixed micelle composition enabled us to liberate GCGR into the gas-phase from both  $NH_4OAc$  and NaCl/Tris (Figure 2B,C). To test receptor functionality we confirmed



**Figure 2.** Preservation of lipophilic drug binding to the glucagon receptor in NaCl-containing electrospray buffers. (A) Structure of the full-length glucagon receptor (PDB 5XEZ) showing the allosteric binding pocket binding NNC0640, a variant of to NNC0666, situated between transmembrane loops VI and VII with interacting residues highlighted in blue. Native mass spectra of GCGR released from G1/CHS micelles in (B) 250 mM NH<sub>4</sub>OAc, pH 7.5 electrospray buffer or (C) 50 mM NaCl, 5 mM Tris, pH 7.5 electrospray buffers with insets expanding the 13+ charge state. Differences in binding of the NNC066 are more prevalent in (C), highlighted orange and red for one and two NAMs, respectively. Spectra are representative of  $n \ge 4$  nanoemitters and n = 2 protein preparations.

binding of the endogenous peptide, glucagon (Figure S13). Unlike A2aR we did not observe sodium binding to GCGR, allowing direct comparison of spectra from both solution conditions. The measured mass of the receptor was 52415.4  $\pm$ 0.5 Da and 52414.9  $\pm$  0.3 Da from both electrospray solutions. Additionally, at equivalent collisional activation conditions, GCGR ions produced from NH<sub>4</sub>OAc exhibited a bimodal charge state distribution with higher charge states observed than NaCl/Tris (22+ to 13+ vs 19+ to 11+). This bimodal distribution likely indicates an unfolded receptor population. In NH<sub>4</sub>OAc and NaCl/Tris, a series of equally spaced peaks, ~203 Da apart, was apparent (Figure 2B,C insets), and assigned to *N*-acetyl-D-glucosamines (HexNac) at four known glycosylated sites on the extracellular domain.<sup>30</sup> Interestingly, for spectra recorded in NaCl/Tris, a second adduct series at 579.1  $\pm$  1.7 Da, with up to two binding events, was apparent for charge states  $\leq$ 16+. Collisional activation revealed that the unknown molecule could be dissociated, suggesting that it was noncovalently bound to the protein (Figure S14A,B). On the basis of the mass, we suspected this molecule was the negative allosteric modulator, NNC0666 (monoisotopic mass = 579.22 Da), present in purification solutions to stabilize GCGR. NNC0666 is a variant of the lipophilic compound NNC0640 (Figure 2A), which is an essential buffer supplement for stabilizing apo GCGR during purification and crystallization processes.<sup>31,32</sup>

To identify ligands associated with GCGR we performed a tandem MS experiment on an Orbitrap Eclipse Tribrid MS platform.<sup>18</sup> Broad isolation of the 13+ charge state (selection window m/z = 100-200) released many species below m/z = 1000 (Figure S15A,B). Focusing on the m/z 574–584 region fragmentation suggested potential lipid fragmentation patterns (Figure S16), whereas fragmentation of m/z 580 ion yielded a pattern consistent with NNC0666 (Figure S15C–E), an assignment subsequently corroborated using a standard solution of NNC0666 (Figure S15F–J).

To compare directly how solution conditions affect binding we quantified the fractional binding of NNC0666 to GCGR in the two different solutions (Figure S17C). We found that 1  $\mu$ M NNC0666 in NaCl/Tris or NH<sub>4</sub>OAc solution achieved 40  $\pm$  5% and 8  $\pm$  2% fractional binding at 1  $\mu$ M, respectively, with an expected value of 17% based on the  $K_d$  value (3–10 nM). Thus, we observe an approximately 5-fold enhancement in the presence of sodium ions.

For Class B GPCRs, sodiums are not expected to affect binding affinity, as in documented cases of monovalent and divalent cations with other GPCRs.<sup>33,34</sup> Thus, it is intriguing that switching from NH<sub>4</sub>OAc to NaCl/Tris affects ligand binding with GCGR. Reduction of the GCGR charge state distribution in NaCl/Tris electrospray buffers suggests that the gas-phase ions produced are more compact. Supplementing higher concentrations of NNC0666 to NH<sub>4</sub>OAc buffers appears to have a similar effect on the charge state distribution (Figure S17A), possibly through better stabilization of the receptor fold during the nano-ESI process. Hence, these results imply that the structural properties necessary for preserving ligand binding in dynamic proteins, such as GPCRs, are better maintained in NaCl/Tris than NH<sub>4</sub>OAc buffer.

Overall, these GPCR examples demonstrate that a fundamental challenge for MS, the use of high salt, can be ameliorated through the use of nanoemitters.<sup>19</sup> Importantly, we also demonstrate with A2aR that nMS can complement other biophysical tools to inform on allosteric effects at the level of individual sodium ions. In the case of GCGR, we show improved lipophilic ligand binding in the sodium-containing buffer, which has implications for preserving protein–ligand binding interactions in drug discovery or the characterization of endogenous ligands from biological systems. We envisage that these developments will help delineate the complex interplay between physiological ions and ligands on modulating GPCRs, and more generally on membrane protein structure and function of other receptors, transporters, and ion channels.

## ASSOCIATED CONTENT

#### **Supporting Information**

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/jacs.0c11837.

Materials and Methods; Figures S1-S18 (PDF)

#### AUTHOR INFORMATION

## **Corresponding Author**

Carol V. Robinson – Department of Chemistry, University of Oxford, Oxford OX1 3TA, U.K.; o orcid.org/0000-0001-7829-5505; Email: carol.robinson@chem.ox.ac.uk

#### Authors

Mark T. Agasid – Department of Chemistry, University of Oxford, Oxford OX1 3TA, U.K.

Lars Sørensen – Global Research Technologies, Novo Nordisk A/S, Måløv 2760, Denmark

Leonhard H. Urner – Department of Chemistry, University of Oxford, Oxford OX1 3TA, U.K.

Jun Yan – Global Research Technologies, Novo Nordisk A/S, Måløv 2760, Denmark

Complete contact information is available at: https://pubs.acs.org/10.1021/jacs.0c11837

#### Notes

The authors declare the following competing financial interest(s): JY is an employee of Novo Nordisk, a pharmaceutical company focused on class B GPCRs for type 2 diabetes. CVR is a cofounder and Director of OMass Therapeutics.

#### ACKNOWLEDGMENTS

The authors would like to thank Robinson Group members for useful discussions, and especially Dr. Joseph Gault for help with the ligand identification experiments. We would also like to thank Mrs. Jennifer Holter and Dr. Neil Young at the David Cockayne Centre for Electron Microscopy located in the Department of Materials (Oxford University) for help imaging nanoemitter tips. CVR is funded by a Wellcome Trust Investigator Award (No. 104633/Z/14/Z) and a Medical Research Council Programme Grant (No. MR/N020413/1).

# REFERENCES

(1) Santos, R.; Ursu, O.; Gaulton, A.; Bento, A. P.; Donadi, R. S.; Bologa, C. G.; Karlsson, A.; Al-Lazikani, B.; Hersey, A.; Oprea, T. I.; Overington, J. P. A comprehensive map of molecular drug targets. *Nat. Rev. Drug Discovery* **2017**, *16* (1), 19–34.

(2) van der Westhuizen, E. T.; Valant, C.; Sexton, P. M.; Christopoulos, A. Endogenous Allosteric Modulators of G Protein-Coupled Receptors. J. Pharmacol. Exp. Ther. 2015, 353 (2), 246–260. (3) Katritch, V.; Fenalti, G.; Abola, E. E.; Roth, B. L.; Cherezov, V.; Stevens, R. C. Allosteric sodium in class A GPCR signaling. Trends Biochem. Sci. 2014, 39 (5), 233–244.

(4) Vickery, O. N.; Carvalheda, C. A.; Zaidi, S. A.; Pisliakov, A. V.; Katritch, V.; Zachariae, U. Intracellular Transfer of Na+ in an Active-State G-Protein-Coupled Receptor. *Structure* **2018**, *26* (1), 171–180. (5) White, K. L.; Eddy, M. T.; Gao, Z. G.; Han, G. W.; Lian, T.; Deary, A.; Patel, N.; Jacobson, K. A.; Katritch, V.; Stevens, R. C. Structural Connection between Activation Microswitch and Allosteric Sodium Site in GPCR Signaling. *Structure* **2018**, *26* (2), 259–269.

(6) Eddy, M. T.; Lee, M. Y.; Gao, Z. G.; White, K. L.; Didenko, T.; Horst, R.; Audet, M.; Stanczak, P.; McClary, K. M.; Han, G. W.; Jacobson, K. A.; Stevens, R. C.; Wuthrich, K. Allosteric Coupling of Drug Binding and Intracellular Signaling in the A(2A) Adenosine Receptor. Cell 2018, 172 (1-2), 68-80.

(7) Chan, H. C. S.; Xu, Y. M.; Tan, L.; Vogel, H.; Cheng, J. J.; Wu, D.; Yuan, S. G. Enhancing the Signaling of GPCRs via Orthosteric Ions. ACS Cent. Sci. 2020, 6 (2), 274–282.

(8) Hu, X. H.; Provasi, D.; Ramsey, S.; Filizola, M. Mechanism of mu-Opioid Receptor-Magnesium Interaction and Positive Allosteric Modulation. *Biophys. J.* **2020**, *118* (4), 909–921.

(9) Massink, A.; Amelia, T.; Karamychev, A.; Ijzerman, A. P. Allosteric modulation of G protein-coupled receptors by amiloride and its derivatives. Perspectives for drug discovery? *Med. Res. Rev.* **2020**, 40 (2), 683–708.

(10) Chan, H. C. S.; Li, Y.; Dahoun, T.; Vogel, H.; Yuan, S. G. New Binding Sites, New Opportunities for GPCR Drug Discovery. *Trends Biochem. Sci.* **2019**, *44* (4), 312–330.

(11) Fronik, P.; Gaiser, B. I.; Pedersen, D. S. Bitopic Ligands and Metastable Binding Sites: Opportunities for G Protein-Coupled Receptor (GPCR) Medicinal Chemistry. *J. Med. Chem.* **2017**, *60* (10), 4126–4134.

(12) Bolla, J. R.; Agasid, M. T.; Mehmood, S.; Robinson, C. V. Membrane Protein-Lipid Interactions Probed Using Mass Spectrometry. *Annu. Rev. Biochem.* **2019**, *88*, 85–111.

(13) Calabrese, A. N.; Radford, S. E. Mass spectrometry-enabled structural biology of membrane proteins. *Methods* **2018**, *147*, 187–205.

(14) Hernandez, H.; Robinson, C. V. Determining the stoichiometry and interactions of macromolecular assemblies from mass spectrometry. *Nat. Protoc.* **2007**, *2* (3), 715–726.

(15) Mehmood, S.; Allison, T. M.; Robinson, C. V. Mass Spectrometry of Protein Complexes: From Origins to Applications. *Annu. Rev. Phys. Chem.* **2015**, *66*, 453–474.

(16) Yen, H. Y.; Hoi, K. K.; Liko, I.; Hedger, G.; Horrell, M. R.; Song, W. L.; Wu, D.; Heine, P.; Warne, T.; Lee, Y.; Carpenter, B.; Pluckthun, A.; Tate, C. G.; Sansom, M. S. P.; Robinson, C. V. PtdIns(4,5)P-2 stabilizes active states of GPCRs and enhances selectivity of G-protein coupling. *Nature* **2018**, *559* (7714), 423–427.

(17) Yen, H. Y.; Hopper, J. T. S.; Liko, I.; Allison, T. M.; Zhu, Y.; Wang, D. J.; Stegmann, M.; Mohammed, S.; Wu, B. L.; Robinson, C. V. Ligand binding to a G protein-coupled receptor captured in a mass spectrometer. *Sci. Adv.* **2017**, *3* (6), No. e1701016.

(18) Gault, J.; Liko, I.; Landreh, M.; Shutin, D.; Bolla, J. R.; Jefferies, D.; Agasid, M.; Yen, H. Y.; Ladds, M. J. G. W.; Lane, D. P.; Khalid, S.; Mullen, C.; Remes, P. M.; Huguet, R.; McAlister, G.; Goodwin, M.; Viner, R.; Syka, J. E. P.; Robinson, C. V. Combining native and 'omics' mass spectrometry to identify endogenous ligands bound to membrane proteins. *Nat. Methods* **2020**, *17* (5), 505–508.

(19) Susa, A. C.; Xia, Z. J.; Williams, E. R. Native Mass Spectrometry from Common Buffers with Salts That Mimic the Extracellular Environment. *Angew. Chem., Int. Ed.* **2017**, *56* (27), 7912–7915.

(20) Hu, J.; Guan, Q. Y.; Wang, J.; Jiang, X. X.; Wu, Z. Q.; Xia, X. H.; Xu, J. J.; Chen, H. Y. Effect of Nanoemitters on Suppressing the Formation of Metal Adduct Ions in Electrospray Ionization Mass Spectrometry. *Anal. Chem.* **2017**, *89* (3), 1838–1845.

(21) Nguyen, G. T. H.; Tran, T. N.; Podgorski, M. N.; Bell, S. G.; Supuran, C. T.; Donald, W. A. Nanoscale Ion Emitters in Native Mass Spectrometry for Measuring Ligand-Protein Binding Affinities. *ACS Cent. Sci.* **2019**, 5 (2), 308–318.

(22) Susa, A. C.; Lippens, J. L.; Xia, Z. J.; Loo, J. A.; Campuzano, I. D. G.; Williams, E. R. Submicrometer Emitter ESI Tips for Native Mass Spectrometry of Membrane Proteins in Ionic and Nonionic Detergents. J. Am. Soc. Mass Spectrom. **2018**, 29 (1), 203–206.

(23) Nehme, R.; Carpenter, B.; Singhal, A.; Strege, A.; Edwards, P. C.; White, C. F.; Du, H. J.; Grisshammer, R.; Tate, C. G. Mini-G proteins: Novel tools for studying GPCRs in their active conformation. *PLoS One* **2017**, *12* (4), No. e0175642.

(24) Dore, A. S.; Robertson, N.; Errey, J. C.; Ng, I.; Hollenstein, K.; Tehan, B.; Hurrell, E.; Bennett, K.; Congreve, M.; Magnani, F.; Tate, C. G.; Weir, M.; Marshall, F. H. Structure of the Adenosine A(2A) Receptor in Complex with ZM241385 and the Xanthines XAC and Caffeine. *Structure* **2011**, *19* (9), 1283–1293.

(25) Naranjo, A. N.; McNeely, P. M.; Katsaras, J.; Robinson, A. S. Impact of purification conditions and history on A(2A) adenosine receptor activity: The role of CHAPS and lipids. *Protein Expression Purif.* **2016**, *124*, 62–67.

(26) Liko, I.; Degiacomi, M. T.; Lee, S.; Newport, T. D.; Gault, J.; Reading, E.; Hopper, J. T. S.; Housden, N. G.; White, P.; Colledge, M.; Sula, A.; Wallace, B. A.; Kleanthous, C.; Stansfeld, P. J.; Bayley, H.; Benesch, J. L. P.; Allison, T. M.; Robinson, C. V. Lipid binding attenuates channel closure of the outer membrane protein OmpF. *Proc. Natl. Acad. Sci. U. S. A.* **2018**, *115* (26), 6691–6696.

(27) Massink, A.; Gutierrez-de-Teran, H.; Lenselink, E. B.; Zacarias, N. V. O.; Xia, L. Z.; Heitman, L. H.; Katritch, V.; Stevens, R. C.; Ijzerman, A. P. Sodium Ion Binding Pocket Mutations and Adenosine A(2A) Receptor Function. *Mol. Pharmacol.* **2015**, *87* (2), 305–313.

(28) Hu, X. H.; Smith, M. D.; Humphreys, B. M.; Green, A. T.; Parks, J. M.; Baudry, J. Y.; Smith, J. C. Ligand-Dependent Sodium Ion Dynamics within the A(2A) Adenosine Receptor: A Molecular Dynamics Study. J. Phys. Chem. B **2019**, 123 (38), 7947–7954.

(29) Urner, L. H.; Liko, I.; Yen, H. Y.; Hoi, K. K.; Bolla, J. R.; Gault, J.; Almeida, F. G.; Schweder, M. P.; Shutin, D.; Ehrmann, S.; Haag, R.; Robinson, C. V.; Pagel, K. Modular detergents tailor the purification and structural analysis of membrane proteins including G-protein coupled receptors. *Nat. Commun.* **2020**, *11* (1), 564.

(30) Unson, C. G. Molecular determinants of glucagon receptor signaling. *Biopolymers* 2002, 66 (4), 218–235.

(31) Siu, F. Y.; He, M.; de Graaf, C.; Han, G. W.; Yang, D. H.; Zhang, Z. Y.; Zhou, C. H.; Xu, Q. P.; Wacker, D.; Joseph, J. S.; Liu, W.; Lau, J.; Cherezov, V.; Katritch, V.; Wang, M. W.; Stevens, R. C. Structure of the human glucagon class B G-protein-coupled receptor. *Nature* **2013**, *499* (7459), 444–449.

(32) Zhang, H. N.; Qiao, A. N.; Yang, D. H.; Yang, L. L.; Dai, A. T.; De Graaf, C.; Reedtz-Runge, S.; Dharmarajan, V.; Zhang, H.; Han, G. W.; Grant, T. D.; Sierra, R. G.; Weierstall, U.; Nelson, G.; Liu, W.; Wu, Y. H.; Ma, L. M.; Cai, X. Q.; Lin, G. Y.; Wu, X. A.; Geng, Z.; Dong, Y. H.; Song, G. J.; Griffin, P. R.; Lau, J.; Chrezov, V.; Yang, H. Y.; Hanson, M. A.; Stevens, R. C.; Zhao, Q.; Jiang, H. L.; Wang, M. W.; Wu, B. L. Structure of the full-length glucagon class B G-proteincoupled receptor. *Nature* **2017**, *546* (7657), 259–264.

(33) Mitra, N.; Liu, Y. T.; Liu, J.; Serebryany, E.; Mooney, V.; DeVree, B. T.; Sunahara, R. K.; Yan, E. C. Y. Calcium-Dependent Ligand Binding and G-protein Signaling of Family B GPCR Parathyroid Hormone 1 Receptor Purified in Nanodiscs. ACS Chem. Biol. 2013, 8 (3), 617–625.

(34) Culhane, K. J.; Belina, M. E.; Sims, J. N.; Cai, Y. Y.; Liu, Y. T.; Wang, P. S. P.; Yan, E. C. Y. Parathyroid Hormone Senses Extracellular Calcium To Modulate Endocrine Signaling upon Binding to the Family B GPCR Parathyroid Hormone 1 Receptor. *ACS Chem. Biol.* **2018**, *13* (8), 2347–2358.